Statistical analyses showed that CD133+ CSCs was significantly more sensitive to fVII-tPDT than CD133- non-CSC cancer cells (p values <0.01 or less) (Figure 4a and 4b, Supplementary Table S3), suggesting that CSCs are actually more sensitive to fVII-tPDT treatment than non-CSC cancer cells. The gene discussed is PROM1; the disease is cancer.